Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: a case report

BMC Infect Dis. 2019 Jan 18;19(1):66. doi: 10.1186/s12879-019-3723-y.

Abstract

Background: Pneumocystis pneumonia (PCP) is a common opportunistic infection caused by Pneumocystis jirovecii. Its incidence at 2 years or more after liver transplant (LT) is < 0.1%. PCP-related spontaneous pneumothorax and/or pneumomediastinum is rare in patients without the human immunodeficiency virus, with an incidence of 0.4-4%.

Case presentation: A 65-year-old woman who had split-graft deceased-donor LT for primary biliary cirrhosis developed fever, dyspnea and dry coughing at 25 months after transplant. Her immunosuppressants included tacrolimus, mycophenolate mofetil, and prednisolone. PCP infection was confirmed by molecular detection of Pneumocystis jirovecii,in bronchoalveolar lavage. On day-10 trimethoprim-sulphamethoxazole, her chest X-ray showed subcutaneous emphysema bilaterally, right pneumothorax and pneumomediastinum. Computed tomography of the thorax confirmed the presence of right pneumothorax, pneumomediastinum and subcutaneous emphysema. She was managed with 7-day right-sided chest drain and a 21-day course of trimethoprim-sulphamethoxazole before discharge.

Conclusion: Longer period of PCP prophylaxis should be considered in patients who have a higher risk compared to general LT patients. High index of clinical suspicion, prompt diagnosis and treatment with ongoing patient reassessment to detect and exclude rare, potentially fatal but treatable complications are essential, especially when clinical deterioration has developed.

Keywords: Pneumocystis jirovecii; Pneumocystis pneumonia; Post-liver transplant; Primary biliary cirrhosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibiotic Prophylaxis
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Liver Transplantation / adverse effects*
  • Mediastinal Emphysema / diagnostic imaging
  • Mediastinal Emphysema / drug therapy
  • Mediastinal Emphysema / microbiology*
  • Pneumocystis carinii / pathogenicity*
  • Pneumonia, Pneumocystis / drug therapy
  • Pneumonia, Pneumocystis / microbiology*
  • Pneumothorax / microbiology*
  • Subcutaneous Emphysema / diagnostic imaging
  • Subcutaneous Emphysema / microbiology
  • Tomography, X-Ray Computed
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Immunosuppressive Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination